Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Perspective Therapeutics Inc CATX

Healthcare Biotechnology

Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. It is also developing imaging diagnostics that... see more

Add To Watchlist

Recent & Breaking News (NYSEAM:CATX)

IsoRay, Inc. to Present at the Planet MicroCap Showcase 2017

Accesswire April 18, 2017

IsoRay Announces Final Court Approval of Class Action Settlement

PR Newswire March 9, 2017

IsoRay Announces Second Quarter Fiscal 2017 Financial Results

PR Newswire February 8, 2017

MicroCap Review Magazine Winter/Spring 2017 Issue Now Available

PR Newswire February 7, 2017

IsoRay, Inc. to Present at the 2nd Annual Disruptive Growth & Healthcare Conference

Accesswire February 2, 2017

Purcell Julie & Lefkowitz LLP Is Investigating IsoRay, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

PR Newswire January 11, 2017

IsoRay Medical, Inc. Discusses Cesium-131 and its Applications in New SNNLive Video Interview on StockNewsNow.com

PR Newswire December 22, 2016

IsoRay, Inc. Announces the Launch of a Pilot Study Using Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Resectable High Risk Recurrent Head and Neck Cancer by Case Comprehensive Cancer Center

PR Newswire December 21, 2016

IsoRay to Present at 9th Annual LD Micro Investor Conference

PR Newswire November 30, 2016

IsoRay Announces "Cesium-131 Brachytherapy for Salvage of Recurrent High Grade Glioma" Poster Presentation at 21st Annual Scientific Meeting of Society for Neuro-Oncology

PR Newswire November 29, 2016

IsoRay Announces First Quarter Fiscal 2017 Financial Results

PR Newswire November 8, 2016

The Rosen Law Firm, P.A. and Wolf Haldenstein Adler Freeman & Herz LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of IsoRay, Inc. -- ISR

GlobeNewswire October 30, 2016

IsoRay, Inc. Announces Date for Fiscal 2017 Annual Meeting and Shareholder Record Date

PR Newswire October 20, 2016

IsoRay, Inc. Announces Launch of Newly Redesigned Patient and Clinician Focused Corporate Website

PR Newswire September 28, 2016

IsoRay, Inc. Enters Into Agreement to Settle Class Action Shareholder Litigation

PR Newswire September 27, 2016

IsoRay Reports Results of Prospective Trial: '95% of Targeted Cancers Showed No Regrowth of Tumor at the Operative Site'

Benzinga.com June 21, 2016

IsoRay® Announces Results of Prospective Trial Presented at Society of Neuro-Oncology Conference

PR Newswire June 21, 2016

Court Issues Ruling on IsoRay Motion to Dismiss Securities Lawsuit

PR Newswire June 2, 2016

IsoRay Provides Update on Motion to Dismiss Securities Lawsuit

PR Newswire May 16, 2016

IsoRay Announces Third Quarter Fiscal 2016 Financial Results and Early Conclusions from Ongoing Strategic Review Process

PR Newswire May 10, 2016